

OTCBB symbol: **NPHC**
Data as of 12/03/09 closing.
Bid 0.40 x 0.415 Ask

NUTRA PHARMA CORPORATION

Last Trade Price	\$ 0.415	<i>Shares Authorized</i>	
52-Week Range	\$ 0.01-0.99	Common Shares	2,000,000,000
Daily High	\$ 0.43	Preferred Shares	0
Daily Low	\$ 0.38	<i>Shares Outstanding</i>	
Market Capitalization	\$ 111.72 M	Common Shares	211,276,482
Average Volume (3 mo.)	1,078,770	Preferred Shares	0

Business Summary

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), and Human Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities. The company's wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena. Nutra Pharma Corporation was founded in 2000 and is based in Boca Raton, Florida.

With the exception of historical information, this document may include forward-looking statements that involve a number of risks and uncertainties. Actual results could differ materially from those anticipated as a result of various risks. There are numerous factors that could contribute to such differences, therefore such projected events and anticipated results are not warranties or guaranties that such events will occur or that the Company will achieve such results. For more information about this corporation and risks involved in the investment of their publicly traded shares, please see the company's website(s), and/or documents filed with the SEC, which are easily accessible in the EDGAR database system.

OTCBB symbol: **NPHC**

Nutra Pharma Corporation
1537 NW 65th Avenue
Plantation, FL 33313

Phone: 954-509-0911
Fax: 877-895-5647
Web Site:
<http://www.nutrapharma.com>

Selected Financial Data Comparison

	12 Months Ended DECEMBER 31, 2008	12 Months Ended DECEMBER 31, 2007
Total Assets	\$ 107,222	\$ 144,185
Total Liabilities	\$ 2,663,556	\$ 2,096,911
Total Expenses	\$ 4,165,096	\$ 164,951
Net Income (indicates loss)	\$ (4,162,108)	\$ (164,951)

Press Releases

[Nutra Pharma Announces Upcoming Webinar to Discuss the Company's Over-the-Counter \(OTC\) and Prescription Treatments for Chronic Pain](#) Business Wire(Thu 9:03am)

[XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation](#) Business Wire(Fri, Nov 27)

[NUTRA PHARMA CORP Financials](#) EDGAR Online Financials(Tue, Nov 24)

[Nutra Pharma Introduces Chronic Pain Reliever, Nyloxin OTC, for International Distribution](#) Business Wire(Thu, Nov 19)

Outstanding Shares :	211,276,482
Estimated Float:	185.61 M
52 week high:	\$0.99
52 week low:	\$ 0.01
Average Volume (3-mo.)	1,078,770

Active Market Makers

BID	ASK
JSUP	VFIN
NITE	NITE
UBSS	HDSN
AUTO	UBSS
DOMS	VERT
HDSN	AUTO
LABS	DOMS
ABLE	JSUP
VERT	LABS
VFIN	PERT
VNDM	VNDM
PERT	ABLE

Top Market Maker by volume (Year-to-Date)

Three Month Chart

